Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:11934
Name head and neck cancer
Definition An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer head and neck cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ALK wild-type Cisplatin + Dalantercept head and neck cancer predicted - sensitive detail...
ATM loss AZD6738 + Olaparib head and neck cancer predicted - sensitive detail...
Unknown unknown Cisplatin + GL-ONC1 + Radiotherapy head and neck cancer not applicable detail...
BRAF G469A Ulixertinib head and neck cancer sensitive detail...
PIK3CA mutant Alpelisib head and neck cancer sensitive detail...
ATM del AZD7648 + Olaparib head and neck cancer sensitive detail...
Unknown unknown AsiDNA head and neck cancer not applicable detail...
Unknown unknown AsiDNA + Olaparib head and neck cancer not applicable detail...
ATM del AZD7648 head and neck cancer sensitive detail...
ATM del Olaparib head and neck cancer sensitive detail...
Unknown unknown AZD7648 + Olaparib head and neck cancer not applicable detail...
Unknown unknown Olaparib head and neck cancer not applicable detail...
Unknown unknown AZD7648 head and neck cancer not applicable detail...
Unknown unknown Cetuximab + Ficlatuzumab head and neck cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00903461 Phase Ib/II EGFR Antisense DNA Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Terminated
NCT00970502 Phase Ib/II Celecoxib + Erlotinib Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed
NCT01218048 Phase II Cisplatin Carboplatin Cetuximab ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed
NCT01588431 Phase II Cetuximab + Cisplatin + Docetaxel Bevacizumab Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Active, not recruiting
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01835626 Phase II Vismodegib Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Completed
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Recruiting
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02051751 Phase I Alpelisib + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed
NCT02107235 Phase I Cisplatin Rigosertib Sodium Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Completed
NCT02113878 Phase I Buparlisib + Cisplatin Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Active, not recruiting
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Active, not recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Active, not recruiting
NCT02841748 Phase II Pembrolizumab A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed
NCT03109873 Phase I Metformin Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer Active, not recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03355560 Phase II Nivolumab Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Recruiting
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Recruiting
NCT03578432 Phase I Everolimus Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy Terminated
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer Recruiting
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Recruiting
NCT04044859 Phase I ADP-A2M4 cells Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Suspended
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting
NCT04440943 CDX-527 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies Recruiting